Replies to post #23 on Myrexis, Inc. (MYRX)

[surf1944]

8:04AM Myrexis presents data on cancer metabolism inhibitor program and data on HSP90 inhibitor program (MYRX) 3.85 : Co announces results for 2 programs. First, it presented five posters on its novel cancer metabolism inhibitor, MPC-9528. The data on multiple aspects of MPC-9528 activity that support that potential for broad spectrum tumoricidal activity alone and in a variety of combinations with other agents. Significantly, MPC-9528 was shown to exhibit synergistic anti-tumor activity when coupled with DNA damaging agents such as DNA alkylating agents and thymidylate synthase inhibitors. Additionally, it presented data on its fully synthetic, orally bioavailable heat shock protein 90 (Hsp90) inhibitor. Co demonstrated that the combination of MPC-3100 with other targeted therapies, showed greater in vivo anti-tumor activity compared to either agent alone. These preclinical data demonstrate the potential of combining MPC-3100 with other targeted cancer therapies in the clinic. Animal studies showed that the pro-drug displayed pharmacokinetics comparable to MPC-3100 and equivalent efficacy, inducing significant tumor regressions. The co expects to advance MPC-3100 to Phase 2 as soon as practicable after completing the Phase 1 study.